Company news
Joincare Pharmaceutical Group Industry Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Guarantees for Controlled Subsidiaries
November 4, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice for Tiange Dingxuan Granules
October 27, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice for Recombinant Humanized Anti-FXI Bispecific Antibody Injection
October 27, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Obtaining Drug Registration Certificate
October 27, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Report for Q3 2026
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on the Profit Distribution Proposal for Q3 2026
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Amendments to Certain Provisions of the Articles of Association
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."2026 "Corporate Value and Return Enhancement" 2.0 Plan
October 26, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Entrusted Loans to the Controlled Subsidiary Jiaozuo Jianfeng
October 23, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Entrusted Loans to the Controlled Subsidiary Jiaozuo Jianfeng
October 19, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026
October 13, 2026
(600380)"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Guarantees for Controlled Subsidiaries
October 9, 2026
Announcement on Obtaining Notice of Approval for Drug Supplementary Application
September 29, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 24, 2026
Announcement on Election of Non-Independent Directors
September 18, 2026
Announcement on Outline of the 2026 Semi-annual Performance Briefing
September 17, 2026
Announcement on Change of Chairman and Adjustment of Members of Special Committees of the Board of Directors
September 11, 2026
Announcement on the Interim Profit Distribution Proposal for 2026
September 4, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 24, 2026
Announcement on Progress in Providing Guarantee for Controlled Subsidiary
August 4, 2026
Announcement on Progress in Providing Entrusted Loans to the Controlled Subsidiary Jiaozuo Jianfeng
July 31, 2026
Announcement on Resolutions of the 3rd Holders' Meeting for the First Stock Ownership Plan
July 27, 2026
Announcement on Obtaining Drug Registration Certificate
July 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 17, 2026
Announcement on the Extension of the Duration of the Second Phase of the Company's Medium-to-Long-Term Business Partnership Shareholding Plan
June 1, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 22, 2026
Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
May 15, 2026
Announcement on Progress and Completion of Transfer Registration Regarding the Holding Subsidiary Livzon Group's Public Tender Offer for Equity Interests of Vietnam IMP Company
May 11, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
May 8, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
May 6, 2026
Announcement on Progress in Holding Subsidiary Livzon Group Publicly Acquiring Equity of Vietnam IMP Company
April 29, 2026
Announcement on Resolutions of the 18th Meeting of the 9th Board of Directors
April 24, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of TSLP Monoclonal Antibody for New Indication
April 7, 2026
Announcement on Company Credit Financing and Providing Financing Guarantee for Subsidiaries
March 31, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Brexpiprazole Microspheres for Injection
March 26, 2026
Announcement on Progress in Holding Subsidiary Livzon Group Planning to Publicly Acquire Equity of Vietnam IMP Company
March 6, 2026
Indicative Announcement on Extension of the Six-month Duration of Phase I of the Medium-and Long-term Business Partner Shareholding Plan
February 2, 2026
Announcement on Resolutions of the 16th Meeting of the 9th Board of Directors
January 30, 2026
Announcement on Appointment of Vice President
January 16, 2026
Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program
January 7, 2026
Announcement on Subsidiary Obtaining PIC/S GMP Certification
December 30, 2025
Indicative Announcement on Acceptance of Marketing Authorization Application for Laikangchita Monoclonal Antibody Injection
December 24, 2025
Announcement on Obtaining Drug Registration Certificate for Maribavir Capsules (Yilikang®)
December 11, 2025
Announcement on the Inclusion of the Company’s Product in the National Medical Insurance Catalog
December 8, 2025
Indicative Announcement on Extension of the Six-month Duration of the Second Phase of the Medium-and Long-term Business Partner Shareholding Plan
December 5, 2025
Announcement on Outline of the Q3 2025 Performance Briefing
November 25, 2025
Announcement on Completion of Deregistration of the Special Account for Funds Raised through Rights Issue
November 24, 2025